Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.
The amylin analog at 5 doses will be compared with placebo when added to a reduced calorie diet and increased physical activity regimen for 42 weeks, said Zealand Pharma.